Although Spithoff and colleagues mention some benefits of legalizing cannabis, they provide more details about the potential harms. The positives are limited to reducing stigma and “realization of therapeutic benefits.”1
It may be difficult for physicians viewing cannabis through the lens of addiction to see any silver lining from legalization. However, there are both individual and public health benefits that should be balanced against possible harms. The first and most immediate benefit is that patients who use cannabis for therapeutic purposes will no longer fear legal sanctions.
Both the US and Canada are currently dealing with an increase in addiction and death from fentanyl, oxycodone and other opiates. Two large studies have shown about a 25% decrease in deaths from opiate overdose associated with the legalization of medical cannabis and the availability of dispensaries.2,3 The recent COMPASS study found that the use of cannabis for chronic pain has a reasonable safety profile and that patients often used it as a substitute for other more harmful drugs, such as opiates, NSAIDS (nonsteroidal anti-inflammatory drugs) and alcohol.4 Harm reduction experts have also expressed concerns that professional societies are jeopardizing patient health by requiring a much higher standard for the prescribing of cannabis over the prescribing of opioids.5
Legalization of cannabis would remove research blockades to begin proper study of cannabidiol. This compound is not associated with a “high,” is not known to be addictive and has antiseizure, antianxiety and antipsychotic properties.6 Up to this point, proper study of cannabidiol and other cannabinoids has been restricted by their criminalized status.
Letters to the editor.
In submitting a letter, you automatically consent to having it appear online/in print. All letters accepted for print will be edited for space and style. See www.cmaj.ca for full versions and competing interests.
Footnotes
Go to cmaj.ca for the full-text version of this letter.
References
- 1.Spithoff S, Emerson B, Spithoff A. Cannabis legalization: adhering to public health best practice. CMAJ 2015;187:1211–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Powell D, Pacula RL, Jacobson M. Do medical marijuana laws reduce addictions and deaths related to pain killers? Cambridge, MA: National Bureau of Economic Research; 2015. July Available: www.nber.org/papers/w21345 (accessed 2015 Oct. 15). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Bachhuber MA, Saloner B, Cunningham CO, et al. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med 2014;174:1668–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Ware MA, Wang T, Shapiro S, et al. COMPASS study team. Cannabis for the management of pain: assessment of safety study (COMPASS). J Pain 2015;16:1233–42. [DOI] [PubMed] [Google Scholar]
- 5.Lake S, Kerr T, Montaner J. Prescribing medical cannabis in Canada: Are we being too cautious? Can J Public Health 2015;106:e328–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.The biology and potential therapeutic effects of cannabidiol. National Institute on Drug Abuse; Available: www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2015/biology-potential-therapeutic-effects-cannabidiol (accessed 2015 Sept. 5). [Google Scholar]